Table 3. Meta-analysis results for the association between the lncRNA SPRY4-IT1 expression level and clinico-pathological parameters.
| Clinicopathological parameters | Studies (n) | Patients (n) | OR (95% CI) | P-value | Heterogeneity | ||
|---|---|---|---|---|---|---|---|
| I2 (%) | Ph | Model | |||||
| Age (≥ 55 vs. < 55 years) | 12 | 1173 | 0.90 (0.70-1.14) | 0.37 | 18 | 0.26 | Fixed |
| Gender (Male vs. Female) | 10 | 1067 | 0.98 (0.76-1.25) | 0.87 | 0.51 | 0 | Fixed |
| Tumor size (≥ 5 cm vs. <5 cm) | 5 | 574 | 1.36 (0.59-3.15) | 0.47 | 81 | <0.001 | Random |
| Invasion depth (T3-T4 vs. T1-T2) | 3 | 341 | 1.85 (0.29-11.98) | 0.52 | 90 | <0.001 | Random |
| Distant metastasis (Yes vs. No) | 5 | 409 | 1.96 (1.24-3.08) | 0.004 | 48 | 0.1 | Fixed |
| Lymph node metastasis (Yes vs. No) | 9 | 780 | 3.96 (1.48-5.54) | <0.001 | 18 | 0.28 | Fixed |
| TNM stage (III-IV vs. I-II) | 12 | 1065 | 3.72 (2.91- 4.76) | <0.001 | 23 | 0.22 | Fixed |
| Tumor differentiation (Poor vs. Moderate/Well) | 7 | 689 | 1.86 (1.35-2.58) | <0.001 | 35 | 0.16 | Fixed |